Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | STAT3 | P40763 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.65 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomenol SCHEMBL24988 | 1.00 | ALOX15 (1.00) | ALOX15CYP3A4STAT3MEN1MAPK1 | |
| Levomenol SCHEMBL2728600 | 1.00 | ALOX15 (1.00) | ALOX15CYP3A4STAT3MEN1MAPK1 | |
| Levomenol SCHEMBL24989 | 1.00 | ALOX15 (1.00) | ALOX15CYP3A4STAT3MEN1MAPK1 | |
| Levomenol SCHEMBL31157846 | 1.00 | ALOX15 (1.00) | ALOX15CYP3A4STAT3MEN1MAPK1 | |
| Levomenol SCHEMBL14515491 | 1.00 | ALOX15 (1.00) | ALOX15CYP3A4STAT3MEN1MAPK1 | |
| Bisabolol SCHEMBL13220166 | 1.00 | ALOX15 (1.00) | ALOX15CYP3A4STAT3MEN1MAPK1 | |
| Levomenol SCHEMBL1245143 | 1.00 | ALOX15 (1.00) | ALOX15CYP3A4STAT3MEN1MAPK1 | |
| Levomenol SCHEMBL4259122 | 1.00 | ALOX15 (1.00) | ALOX15CYP3A4STAT3MEN1MAPK1 | |
| Levomenol SCHEMBL20838984 | 1.00 | ALOX15 (1.00) | ALOX15CYP3A4STAT3MEN1MAPK1 | |
| Levomenol SCHEMBL172398 | 1.00 | ALOX15 (1.00) | ALOX15CYP3A4STAT3MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073252-A1 | NON-PSYCHOACTIVE MULTI-CANNABINOID AND TERPENE-BASED THERAPEUTIC COMPOSITIONS AND METHODS OF THEIR ADMINISTRATION | PEBBLE GLOBAL HOLDINGS (US) | 2025-03-06 | — | — | US | claimed |
| US-20240148759-A1 | Non-Psychoactive Multi-Cannabinoid And Terpene-Based Therapeutic Compositions And Methods Of Their Administration | PEBBLE GLOBAL HOLDINGS (US) | 2024-05-09 | — | — | US | claimed |
| WO-2026099321-A1 | TREATMENT OF MITE INFESTATION | VETO-PHARMA (FR) | 2026-05-15 | — | — | WO | disclosed |
| EP-4740734-A1 | TREATMENT OF MITE INFESTATION | Veto-Pharma (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4646426-A1 | HOST CELLS CAPABLE OF PRODUCING SEQUITERPENOIDS AND METHODS OF USE THEREOF | Amyris, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250073252-A1 | NON-PSYCHOACTIVE MULTI-CANNABINOID AND TERPENE-BASED THERAPEUTIC COMPOSITIONS AND METHODS OF THEIR ADMINISTRATION | PEBBLE GLOBAL HOLDINGS (US) | 2025-03-06 | — | — | US | disclosed |
| US-20240225970-A1 | A METHOD OF REDUCING SKIN IRRITATION, COMPRISING THE APPLICATION TO THE SKIN OF AN ALPHA-BISABOLOL PREPARED BY A BIOTECHNOLOGICAL PROCESS | GIVAUDAN SA (CH) | 2024-07-11 | — | — | US | disclosed |
| US-20240225970-A1 | A METHOD OF REDUCING SKIN IRRITATION, COMPRISING THE APPLICATION TO THE SKIN OF AN ALPHA-BISABOLOL PREPARED BY A BIOTECHNOLOGICAL PROCESS | GIVAUDAN SA (CH) | 2024-07-11 | — | — | US | disclosed |
| WO-2024147836-A1 | HOST CELLS CAPABLE OF PRODUCING SEQUITERPENOIDS AND METHODS OF USE THEREOF | Amyris, Inc. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240148759-A1 | Non-Psychoactive Multi-Cannabinoid And Terpene-Based Therapeutic Compositions And Methods Of Their Administration | PEBBLE GLOBAL HOLDINGS (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240066005-A1 | FORMULATIONS FOR TREATING CLUSTER SYMPTOMS ASSOCIATED WITH AUTISM SPECTRUM DISORDER | ILERA THERAPEUTICS LLC | 2024-02-29 | — | — | US | disclosed |
| US-20160250270-A1 | COMPOSITIONS COMPRISING COMBINATIONS OF PURIFIED CANNABINOIDS, WITH AT LEAST ONE FLAVONOID, TERPENE, OR MINERAL | CANOPY GROWTH CORPORATION (CA) | 2016-09-01 | — | — | US | disclosed |
| US-20150064122-A1 | SKIN AND/OR HAIR WHITENING MIXTURE | SYMRISE AG (DE) | 2015-03-05 | — | — | US | disclosed |
| US-20150064122-A1 | SKIN AND/OR HAIR WHITENING MIXTURE | SYMRISE AG (DE) | 2015-03-05 | — | — | US | disclosed |
| US-20110162668-A1 | PERSONAL CARE COMPOSITIONS COMPRISING A MULTI-ACTIVE SYSTEM FOR DOWN REGULATING CYTOKINES IRRITATION | THE GILLETTE COMPANY LLC | 2011-07-07 | — | — | US | disclosed |
| US-20110162668-A1 | PERSONAL CARE COMPOSITIONS COMPRISING A MULTI-ACTIVE SYSTEM FOR DOWN REGULATING CYTOKINES IRRITATION | THE GILLETTE COMPANY LLC | 2011-07-07 | — | — | US | disclosed |
| US-7622617-B2 | Method for producing α-bisabolol from farnesol | BASF SE (DE) | 2009-11-24 | — | — | US | disclosed |
| US-7622617-B2 | Method for producing α-bisabolol from farnesol | BASF SE (DE) | 2009-11-24 | — | — | US | disclosed |
| US-20080269530-A1 | Method for Producing Alpha-Bisabolol from Farnesol | BASF SE (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269530-A1 | Method for Producing Alpha-Bisabolol from Farnesol | BASF SE (DE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110162668-A1 | PERSONAL CARE COMPOSITIONS COMPRISING A MULTI-ACTIVE SYSTEM FOR DOWN REGULATING CYTOKINES IRRITATION | IL36G, IL33, STAT6 | ALOX15 127/4885CYP3A4 3748/4885STAT3 44/4885 |
| US-20150064122-A1 | SKIN AND/OR HAIR WHITENING MIXTURE | TYR, AHR, CYP1B1 | ALOX15 758/4885CYP3A4 231/4885STAT3 4323/4885 |
| US-20240066005-A1 | FORMULATIONS FOR TREATING CLUSTER SYMPTOMS ASSOCIATED WITH AUTISM SPECTRUM DISORDER | CNR2, CNR1, GPR18 | ALOX15 292/4885CYP3A4 1869/4885STAT3 3474/4885 |
| US-20240225970-A1 | A METHOD OF REDUCING SKIN IRRITATION, COMPRISING THE APPLICATION TO THE SKIN OF AN ALPHA-BISABOLOL PREPARED BY A BIOTECHNOLOGICAL PROCESS | FHIT, CUTA, BCHE | ALOX15 1827/4885CYP3A4 275/4885STAT3 4705/4885 |
| US-20160250270-A1 | COMPOSITIONS COMPRISING COMBINATIONS OF PURIFIED CANNABINOIDS, WITH AT LEAST ONE FLAVONOID, TERPENE, OR MINERAL | CNR2, CNR1, MAG | ALOX15 1789/4885CYP3A4 1000/4885STAT3 3725/4885 |
| US-20080269530-A1 | Method for Producing Alpha-Bisabolol from Farnesol | FHIT, FDPS, FASN | ALOX15 1781/4885CYP3A4 163/4885STAT3 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.